GSE185872 methotrexate macrophage 0 v 2 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE185872_methotrexate_macrophage_0_v_2_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE185872_methotrexate_macrophage_0_v_2_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE185872_methotrexate_macrophage_0_v_2_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE185872_methotrexate_macrophage_0_v_2_human_up.

Results found

Linked to

 

Label

Description

 

Gene

tripartite motif containing 31

Gene

p53 regulated carcinoma associated Stat3 activating long intergenic non-protein coding transcript

Gene

SOX21 antisense RNA 1

Gene

TGIF2-RAB5IF readthrough

Gene

transmembrane protein 217B

Gene

damage induced long noncoding RNA

Gene

TTC23L antisense RNA 1

Gene

periphilin-1

Gene

uncharacterized LOC101927369

Gene

ECE1 antisense RNA 1

  • Gene

    tripartite motif containing 31


  • Gene

    p53 regulated carcinoma associated Stat3 activating long intergenic non-protein coding transcript


  • Gene

    SOX21 antisense RNA 1


  • Gene

    TGIF2-RAB5IF readthrough


  • Gene

    transmembrane protein 217B


  • Gene

    damage induced long noncoding RNA


  • Gene

    TTC23L antisense RNA 1



  • Gene

    uncharacterized LOC101927369


  • Gene

    ECE1 antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.